Increased striatal gray matter densities in patients with schizophrenia and substance use disorder: a voxel-based morphometry study

Stéphane Potvin; Adham Mancini-Marïe; Chérine Fahim; Boualem Mensour; Johanne Lévesque; Sherif Karama; Mario Beauregard; Pierre-Paul Rompré; Emmanuel Stip

doi:10.1016/j.pscychresns.2006.11.009

Increased striatal gray matter densities in patients with schizophrenia and substance use disorder: a voxel-based morphometry study

Psychiatry Res. 2007 Apr 15;154(3):275-9. doi: 10.1016/j.pscychresns.2006.11.009. Epub 2007 Mar 6.

Authors

Stéphane Potvin¹, Adham Mancini-Marïe, Chérine Fahim, Boualem Mensour, Johanne Lévesque, Sherif Karama, Mario Beauregard, Pierre-Paul Rompré, Emmanuel Stip

Affiliation

¹ Department of Psychiatry, Fernand-Seguin Research Center, University of Montreal, Canada.

PMID: 17341445
DOI: 10.1016/j.pscychresns.2006.11.009

Abstract

We sought to investigate the link between substance abuse and increased striatal gray matter densities (GMD) in schizophrenia, using voxel-based morphometry (VBM). Increased striatal GMD were found in patients with schizophrenia and substance use disorder (n=12), but not schizophrenia only patients (n=11), compared to healthy volunteers (n=15).

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Antipsychotic Agents / pharmacology
Antipsychotic Agents / therapeutic use
Cell Count
Corpus Striatum / drug effects
Corpus Striatum / pathology*
Diagnostic and Statistical Manual of Mental Disorders
Female
Haloperidol / pharmacology
Haloperidol / therapeutic use
Humans
Magnetic Resonance Spectroscopy
Male
Receptors, Dopamine D2 / drug effects
Schizophrenia* / drug therapy
Schizophrenia* / epidemiology
Schizophrenia* / pathology
Severity of Illness Index
Substance-Related Disorders / diagnosis
Substance-Related Disorders / epidemiology*

Substances

Antipsychotic Agents
Receptors, Dopamine D2
Haloperidol